Amneal Pharmaceuticals, Inc.
AMRX· Nasdaq
AMRXAmneal Pharmaceuticals, Inc.
Filed Mar 3, 2023 · 10-K · 62 days after period end · 0001723128-23-000009
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $609.76M | $536.90M | $510.03M | $397.33M |
| Net Income | -$12.03M | -$21.80M | -$6.83M | -$64.90M |
| EPS Diluted | — | — |
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
| — |
| -$0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 3, 2023 · 62 d after period end
